DCGI grants SII permission to manufacture Sputnik V for specific regulatory purposes
Jun 04, 2021
New Delhi [India], June 4 : The Drug Controller General of India (DCGI) on Friday granted the approval to the Serum Institute of India (SII) for the initial manufacture of the Russian COVID-19 vaccine Sputnik V for testing, examination, and analysis purposes with certain conditions at its licensed facility in Hadapsar, Pune.